Engineering <i>Escherichia coli</i> NfsB To Activate a Hypoxia-Resistant Analogue of the PET Probe EF5 To Enable Non-Invasive Imaging during Enzyme Prodrug Therapy.

Williams, Elsie M; Rich, Michelle H; Mowday, Alexandra M; Ashoorzadeh, Amir; Copp, Janine N; Guise, Christopher P; Anderson, Robert F; Flanagan, Jack U; Smaill, Jeff B; Patterson, Adam V; Ackerley, David F

Engineering Escherichia coli NfsB To Activate a Hypoxia-Resistant Analogue of the PET Probe EF5 To Enable Non-Invasive Imaging during Enzyme Prodrug Therapy.

Williams, Elsie M; Rich, Michelle H; Mowday, Alexandra M; Ashoorzadeh, Amir; Copp, Janine N; Guise, Christopher P; Anderson, Robert F; Flanagan, Jack U; Smaill, Jeff B; Patterson, Adam V; Ackerley, David F.

Afiliación

Williams EM; School of Biological Sciences , Victoria University of Wellington , Wellington 6012 , New Zealand.
Rich MH; School of Biological Sciences , Victoria University of Wellington , Wellington 6012 , New Zealand.
Mowday AM; Auckland Cancer Society Research Centre, School of Medical Sciences , The University of Auckland , Auckland 1023 , New Zealand.
Ashoorzadeh A; Auckland Cancer Society Research Centre, School of Medical Sciences , The University of Auckland , Auckland 1023 , New Zealand.
Copp JN; School of Biological Sciences , Victoria University of Wellington , Wellington 6012 , New Zealand.
Guise CP; Auckland Cancer Society Research Centre, School of Medical Sciences , The University of Auckland , Auckland 1023 , New Zealand.
Anderson RF; Maurice Wilkins Centre for Molecular Biodiscovery , Auckland 1023 , New Zealand.
Flanagan JU; Auckland Cancer Society Research Centre, School of Medical Sciences , The University of Auckland , Auckland 1023 , New Zealand.
Smaill JB; Maurice Wilkins Centre for Molecular Biodiscovery , Auckland 1023 , New Zealand.
Patterson AV; Auckland Cancer Society Research Centre, School of Medical Sciences , The University of Auckland , Auckland 1023 , New Zealand.
Ackerley DF; Maurice Wilkins Centre for Molecular Biodiscovery , Auckland 1023 , New Zealand.

Biochemistry ; 58(35): 3700-3710, 2019 09 03.

Article en En | MEDLINE | ID: mdl-31403283

Asunto(s)

Monitoreo de Drogas/métodos; Proteínas de Escherichia coli/metabolismo; Etanidazol/análogos & derivados; Hidrocarburos Fluorados/metabolismo; Imagen Molecular/métodos; Nitroimidazoles/uso terapéutico; Nitrorreductasas/metabolismo; Tomografía de Emisión de Positrones/métodos; Profármacos/uso terapéutico; Antineoplásicos/uso terapéutico; Técnicas Biosensibles/métodos; Hipoxia de la Célula/fisiología; Activación Enzimática; Escherichia coli/enzimología; Escherichia coli/genética; Proteínas de Escherichia coli/genética; Etanidazol/química; Etanidazol/metabolismo; Terapia Genética/métodos; Células HCT116; Humanos; Hidrocarburos Fluorados/química; Imidazoles/farmacología; Imidazoles/uso terapéutico; Neoplasias/tratamiento farmacológico; Neoplasias/metabolismo; Neoplasias/patología; Nitroimidazoles/farmacología; Nitrorreductasas/genética; Profármacos/metabolismo; Ingeniería de Proteínas

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Nitrorreductasas / Profármacos / Monitoreo de Drogas / Etanidazol / Proteínas de Escherichia coli / Tomografía de Emisión de Positrones / Imagen Molecular / Hidrocarburos Fluorados / Nitroimidazoles Límite: Humans Idioma: En Revista: Biochemistry Año: 2019 Tipo del documento: Article País de afiliación: Nueva Zelanda

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google